Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders | Business Wire
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year | BioSpace
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
sage-10k_20181231.htm
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Rx Product News: April 2023
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Jorge Luna on LinkedIn: So proud of my amazing team who won the Sage Therapeutics 2019 Field… | 59 comments
Bipolar Depression: How do we treat it?
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Zulresso: the world's first post-partum depression drug - Pharmaceutical Technology
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Could Be In For A Depressing FDA Review (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20191231.htm
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Announces Results of FDA Breakthrough Therapy Meeting – ISPE Boston
Small Clinical Trials Lead To Big Results
Sage surges after depression drug gets rapid path to approval - PMLiVE
Proper Résumés - Résumés that stand out and breakthrough applicant tracking systems. | Facebook
SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
Sage advice: psychiatric drug development is tough | Evaluate
Rx Product News: April 2023
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
